Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML.

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Blood

• Publication date

  2004-09-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1182/BLOOD-2004-02-0712PMID 15178581
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The structural basis for autoinhibition of FLT3 by the juxtamembrane domain.

  2004cited by this paper
• FLT3 mutations in childhood acute lymphoblastic leukemia.

  2004cited by this paper
• An innovative phase I clinical study demonstrates inhibition of FLT3 phosphorylation by SU11248 in acute myeloid leukemia patients.

  2003cited by this paper
• The role of FLT3 in haematopoietic malignancies

  2003cited by this paper
• A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia.

  2003cited by this paper
• The roles of FLT3 in hematopoiesis and leukemia.

  2002cited by this paper
• PML/RARα and FLT3-ITD induce an APL-like disease in a mouse model

  2002cited by this paper
• Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412.

  2002cited by this paper
• Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.

  2002cited by this paper
• Amplification of a novel c-Kit activating mutation Asn(822)-Lys in the Kasumi-1 cell line: a t(8;21)-Kit mutant model for acute myeloid leukemia.

  2002cited by this paper
• FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model.

  2002cited by this paper
• PML/RARalpha and FLT3-ITD induce an APL-like disease in a mouse model.

  2002cited by this paper
• Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.

  2001cited by this paper
• Identification of novel FLT‐3 Asp835 mutations in adult acute myeloid leukaemia

  2001cited by this paper
• Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor

  2001cited by this paper
• A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations.

  2001cited by this paper
• Internal tandem duplications of the FLT3 and MLL genes are mainly observed in atypical cases of therapy-related acute myeloid leukemia with a normal karyotype and are unrelated to type of previous therapy

  2001cited by this paper
• Automated genotyping using the DNA MassArray technology.

  2001cited by this paper
• Primer3 on the WWW for general users and for biologist programmers.

  2000cited by this paper
• In vivo treatment of mutant FLT3-transformed murine leukemia with a tyrosine kinase inhibitor

  2000cited by this paper
• Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.

  1996cited by this paper
• Signaling through the hematopoietic cytokine receptors.

  1995cited by this paper
• SETOR: hardware-lighted three-dimensional solid model representations of macromolecules.

  1993cited by this paper
• Improved methods for building protein models in electron density maps and the location of errors in these models.

  1991cited by this paper

• Using genomics to refine pediatric AML risk stratification.

  2025cites this paper
• Mutation spectrum of FLT3 and significance of non‐canonical FLT3 mutations in haematological malignancy

  2023cites this paper
• Mutations of RAS genes identified in acute myeloid leukemia affect glycerophospholipid metabolism pathway

  2023cites this paper
• Exploring the Resistance Mechanisms of Distal D835V Mutation in FLT3 to Inhibitors

  2022cites this paper
• Relation between FMS-like tyrosine kinase 3 factor and hematological parameter in acute lymphoblastic leukemia patients by flow cytometry

  2022cites this paper
• Potential targeting of FLT3 acute myeloid leukemia

  2021cites this paper
• Genomic Abnormalities as Biomarkers and Therapeutic Targets in Acute Myeloid Leukemia

  2021cites this paper
• Role of FLT3 in Acute Myeloid Leukemia: Molecular mechanisms and Therapeutic opportunities Moharram, Sausan

  2021cites this paper
• Diagnostic and therapeutic pitfalls in NPM1-mutated AML: notes from the field

  2021cites this paper
• Novel Approaches to Target Mutant FLT3 Leukaemia

  2020cites this paper
• Potential targeting of FLT3 AML.

  2020cites this paper
• Acute Myeloid Leukemia Case Harboring Unusual FLT3 Variant: Somatic vs Germline?

  2020cites this paper
• Mutations within the Activation Loop Domain of FLT3 in Two Pediatric Patients with Refractory Infant Acute Myeloid Leukemia

  2020cites this paper
• Potential targeting of FLT3 acute myeloid leukemia

  2020cites this paper
• Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations.

  2020cites this paper
• Pharmacological Impact of FLT3 Mutations on Receptor Activity and Responsiveness to Tyrosine Kinase Inhibitors.

  2020cites this paper
• The mutational spectrum of FLT3 gene in acute lymphoblastic leukemia is different from acute myeloid leukemia

  2019cites this paper
• FMS-like Tyrosine Kinase 3/FLT3: From Basic Science to Clinical Implications.

  2019cites this paper
• Could Immunophenotype Guide Molecular Analysis in Patients with Myeloid Malignancies

  2019cites this paper
• Targeting Oncogenic Signaling in Mutant FLT3 Acute Myeloid Leukemia: The Path to Least Resistance

  2018cites this paper
• Spotlight on midostaurin in the treatment of FLT3-mutated acute myeloid leukemia and systemic mastocytosis: design, development, and potential place in therapy

  2017cites this paper
• FLT3 activating mutations display differential sensitivity to multiple tyrosine kinase inhibitors

  2017cites this paper
• Charakterisierung von FLT3 assoziierten Signaltransduktionsproteinen und TET2 als epigenetischer Regulator in der akuten myeloischen Leukämie

  2017cites this paper
• Microenvironnement médullaire et résistance des LAM FLT3-ITD aux inhibiteurs de tyrosine kinase : Rôle pivot du récepteur TAM AXL

  2017cites this paper
• Optimization of allele specific PCR (AS-PCR) for the early detection of FLT3 (D835Y) mutation in Acute Myeloid Leukemia patients at Tabuk, Saudi Arabia.

  2017cites this paper
• Discovery of a Highly Potent and Selective Indenoindolone Type 1 Pan-FLT3 Inhibitor.

  2016cites this paper
• Class III Receptor Tyrosine Kinases in Acute Leukemia – Biological Functions and Modern Laboratory Analysis

  2015cites this paper
• Activating FLT3 Mutants Show Distinct Gain-of-Function Phenotypes In Vitro and a Characteristic Signaling Pathway Profile Associated with Prognosis in Acute Myeloid Leukemia

  2014cites this paper
• The role of Hoxb8 in myeloid progenitor cell immortalisation

  2013cites this paper
• Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors

  2013cites this paper
• tandem duplications in patients with acute myeloid leukemia and have a significantly more favorable prognosis than FLT3 internal FLT3 tyrosine kinase domain mutations are biologically distinct from

  2013cites this paper
• Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome

  2013cites this paper
• Sorafenib treatment of FLT 3-ITD + acute myeloid leukemia : favorable initial outcome and mechanisms of subsequent non-responsiveness associated with the emergence of a D 835 mutation Short-title : New D 835 clone in sorafenib treated FLT 3-ITD + AML

  2012cites this paper
• Sorafenib treatment of FLT 3-ITD acute myeloid leukemia : favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D 835 mutation

  2012cites this paper
• FLT3 and NPM1 mutations in a cohort of AML patients and detection of a novel mutation in tyrosine kinase domain of FLT3 gene from Western India

  2012cites this paper
• Combination of Sleeping Beauty transposition and chemically induced dimerization selection for robust production of engineered cells

  2012cites this paper
• mutation outcome and mechanisms of subsequent non-responsiveness associated acute myeloid leukemia : favorable initial + Sorafenib treatment of FLT 3-ITD

  2012cites this paper
• An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment

  2012cites this paper
• Sorafenib treatment of FLT3-ITD(+) acute myeloid leukemia: favorable initial outcome and mechanisms of subsequent nonresponsiveness associated with the emergence of a D835 mutation.

  2012cites this paper
• Understanding the Molecular and Functional Mechanisms that Underlie Pharamcogenomics-Based Therapy

  2012cites this paper
• Reversible Resistance Induced by FLT3 Inhibition: A Novel Resistance Mechanism in Mutant FLT3-Expressing Cells

  2011cites this paper
• Emerging FMS-like tyrosine kinase 3 inhibitors for the treatment of acute myelogenous leukemia

  2011influential citation
• An integrated genomic approach to the assessment and treatment of acute myeloid leukemia.

  2011cites this paper
• Causative Factors Involved in Development of Resistance to Tyrosine Kinase Inhibition and Novel Strategies Designed to Override This Resistance

  2011cites this paper
• Drug resistance in mutant FLT3-positive AML

  2010cites this paper
• Strukturbasierte Entwicklung von Assaysystemen und Charakterisierung von orthosterischen und allosterischen Kinaseinhibitoren

  2010cites this paper
• Antileukemic Effects of Novel First- and Second-Generation FLT3 Inhibitors: Structure-Affinity Comparison.

  2010cites this paper
• Smac mimetics: implications for enhancement of targeted therapies in leukemia

  2010cites this paper
• Proteus in the World of Proteins: Conformational Changes in Protein Kinases

  2010cites this paper
• Wnt/β-catenin Pathway Modulates the Sensitivity of the Mutant FLT3 Receptor Kinase Inhibitors in a GSK-3β Dependent Manner.

  2010cites this paper
• Phase I/II study of combination therapy with sorafenib, idarubicin, and cytarabine in younger patients with acute myeloid leukemia.

  2010cites this paper
• Discovery and Characterization of Novel Mutant FLT3 Kinase Inhibitors

  2010cites this paper
• Molecular Cancer apeutics apeutic Discovery overy and Characterization of Novel Mutant Ther 3 Kinase Inhibitors

  2010cites this paper
• The clinical and biological consequences of different FLT3 mutations in patients with AML

  2009cites this paper
• Our changing view of the genomic landscape of cancer

  2009cites this paper
• LT 3 inhibition and mechanisms of drug resistance in mutant FLT 3-positive AML

  2009influential citation
• FMS-like tyrosine kinase 3-internal tandem duplication tyrosine kinase inhibitors display a nonoverlapping profile of resistance mutations in vitro.

  2009cites this paper
• FLT3 inhibition and mechanisms of drug resistance in mutant FLT3-positive AML.

  2009cites this paper
• Synthesis of a resorcylic acid lactone (RAL) library using fluorous-mixture synthesis and profile of its selectivity against a panel of kinases.

  2009cites this paper
• Untersuchungen zur Signaltransduktion in Zellinien der Akuten Myeloischen Leukämie mit Mutationen der Rezeptortyrosinkinase

  2009cites this paper
• Antileukemic effects of the novel, mutant FLT3 inhibitor NVP-AST487: effects on PKC412-sensitive and -resistant FLT3-expressing cells.

  2008cites this paper
• Small molecules ATP-competitive inhibitors of FLT3: a chemical overview.

  2008cites this paper
• An FLT3 gene-expression signature predicts clinical outcome in normal karyotype AML.

  2008cites this paper
• Potentiation of antileukemic therapies by the dual PI3K/PDK-1 inhibitor, BAG956: effects on BCR-ABL- and mutant FLT3-expressing cells.

  2008cites this paper
• Soluble phosphorylated fms-like tyrosine kinase III. FLT3 protein in patients with acute myeloid leukemia (AML).

  2007cites this paper
• Cytogenetic findings and clinical outcomes of adult acute myeloid leukaemia patients

  2007cites this paper
• Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines

  2007cites this paper
• New molecular therapy targets in acute myeloid leukemia.

  2007cites this paper
• FLT3 tyrosine kinase domain mutations are biologically distinct from and have a significantly more favorable prognosis than FLT3 internal tandem duplications in patients with acute myeloid leukemia.

  2007cites this paper
• The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272

  2007cites this paper
• FLT3 as a therapeutic target in childhood acute leukemia.

  2007cites this paper
• Importance of early detection and follow-up of FLT3 mutations in patients with acute myeloid leukemia

  2007cites this paper
• FLT3 kinase inhibitors in the management of acute myeloid leukemia.

  2007cites this paper
• Potentiation of antileukemic therapies by Smac mimetic, LBW242: effects on mutant FLT3-expressing cells

  2007cites this paper
• High-throughput oncogene mutation profiling in human cancer

  2007cites this paper
• D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia

  2007cites this paper
• Molecular Insights in MLL Rearranged Acute Leukemia

  2006cites this paper
• Lineage dependency and lineage-survival oncogenes in human cancer

  2006cites this paper
• New agents for the treatment of acute myeloid leukemia.

  2006cites this paper
• Impact of BCR/ABL gene expression on the proliferative rate of different subpopulations of haematopoietic cells in chronic myeloid leukaemia

  2006cites this paper
• Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.

  2006cites this paper
• Genomic Approaches to Lung Cancer

  2006cites this paper
• Why do chronic myelogenous leukemia stem cells survive allogeneic stem cell transplantation or imatinib: does it really matter?

  2006cites this paper
• A transforming MET mutation discovered in non-small cell lung cancer using microarray-based resequencing.

  2006cites this paper
• Molecular regulation of receptor tyrosine kinases in hematopoietic malignancies.

  2006cites this paper
• Emerging Flt3 kinase inhibitors in the treatment of leukaemia

  2006cites this paper
• FMS‐Like Tyrosine Kinase 3 in Normal Hematopoiesis and Acute Myeloid Leukemia

  2006cites this paper
• FLT3 K663Q is a novel AML-associated oncogenic kinase: determination of biochemical properties and sensitivity to Sunitinib (SU11248)

  2006cites this paper
• Anticipating the $1,000 genome

  2006cites this paper
• Mutant FLT3 signaling contributes to a block in myeloid differentiation

  2005cites this paper
• AML-associated Flt3 kinase domain mutations show signal transduction differences compared with Flt3 ITD mutations.

  2005cites this paper
• Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression.

  2005cites this paper
• FLT3-ITD and tyrosine kinase domain mutants induce 2 distinct phenotypes in a murine bone marrow transplantation model.

  2005cites this paper
• Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics

  2005cites this paper
• Genetics of myeloid malignancies: pathogenetic and clinical implications.

  2005cites this paper
• A novel FLT3 activation loop mutation N841K in acute myeloblastic leukemia

  2005cites this paper
• Src family tyrosine kinases are activated by Flt3 and are involved in the proliferative effects of leukemia-associated Flt3 mutations.

  2005cites this paper
• Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).

  2005cites this paper
• Signal Transduction of Oncogenic Flt3

  2005cites this paper
• AML-associated Flt 3 kinase domain mutations show signal transduction differences compared with Flt 3 ITD mutations

  2005cites this paper